97 related articles for article (PubMed ID: 12648895)
1. The clinical use of milnacipran for depression.
Morishita S; Arita S
Eur Psychiatry; 2003 Feb; 18(1):34-5. PubMed ID: 12648895
[TBL] [Abstract][Full Text] [Related]
2. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
[TBL] [Abstract][Full Text] [Related]
3. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T
Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
[TBL] [Abstract][Full Text] [Related]
4. Controlled comparison of two different doses of milnacipran in major depressive outpatients.
Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T
Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc G;
Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
[TBL] [Abstract][Full Text] [Related]
8. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression.
Van Amerongen AP; Ferrey G; Tournoux A
J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
[TBL] [Abstract][Full Text] [Related]
11. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.
Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G
Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214
[TBL] [Abstract][Full Text] [Related]
12. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
[TBL] [Abstract][Full Text] [Related]
13. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
[TBL] [Abstract][Full Text] [Related]
14. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
[TBL] [Abstract][Full Text] [Related]
15. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of milnacipran by risperidone in treatment for major depression.
Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N
Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310
[TBL] [Abstract][Full Text] [Related]
17. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Okumura K; Furukawa TA
Clin Drug Investig; 2006; 26(3):135-42. PubMed ID: 17163244
[TBL] [Abstract][Full Text] [Related]
18. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
[TBL] [Abstract][Full Text] [Related]
19. Milnacipran treatment of a terminally ill cancer patient with major depressive disorder.
Sato K; Higuchi H; Yoshida K; Takahashi H; Shimizu T; Watanabe J
Hum Psychopharmacol; 2004 Aug; 19(6):431-2. PubMed ID: 15303248
[No Abstract] [Full Text] [Related]
20. Controlled comparison of milnacipran and fluoxetine in major depression.
Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J
Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
